Kumar, Shiva MD, MHA1; Miller, Charles M. MD2; Hashimoto, Koji MD, PhD2; Quintini, Cristiano MD2; Kumar, Arun MD3; Balci, Numan C. MD4; Pinna, Antonio D. MD, PhD1
doi : 10.1097/TP.0000000000003455
September 2021 - Volume 105 - Issue 9 - p 1881-1883
Singh, Prince MD1; Luo, Xunrong MD, PhD1
doi : 10.1097/TP.0000000000003906
September 2021 - Volume 105 - Issue 9 - p 1884-1885
Schurink, Ivo J. BSc1; de Jonge, Jeroen MD, PhD1; van der Laan, Luc J.W. PhD1
doi : 10.1097/TP.0000000000003790
September 2021 - Volume 105 - Issue 9 - p 1886-1887
Kim, Yunmi MD1; Ahmed, Ejaz MD2; Ascher, Nancy MD, PhD3; Danguilan, Romina MD4; Hooi, Lai Seong MBBChir5; Hustrini, Ni Made MD6; Kim, Yeong Hoon MD7; Kute, Vivek MD8; Rosete-Liquete, Rose Marie O. MD9; Ma, Maggie MD10; Mannon, Roslyn B. MD, PhD11; Nakagawa, Yuki MD12,13; Od-Erdne, Lkhaakhuu MD13; Ramesh, Vasanthi MD14; Rashid, Harun Ur MD15; Thangaraju, Sobhana MD16; Thwin, Khin Thida MD17; Vathsala, Anantharaman BS, MD18; West, Lori MD, PhD19; Win, Khin Khin MD20; Ahn, Curie MD, PhD21; Wong, Germaine MBBS, PhD22,23
doi : 10.1097/TP.0000000000003841
September 2021 - Volume 105 - Issue 9 - p 1888-1891
Schlegel, Andrea MD1,2; Foley, David P. MD3; Savier, Eric MD4; Flores Carvalho, Mauricio BSc2; De Carlis, Luciano MD5,6; Heaton, Nigel MD7; Taner, C. Burcin MD8
doi : 10.1097/TP.0000000000003825
September 2021 - Volume 105 - Issue 9 - p 1892-1903
Although the utilization of donation after circulatory death donors (DCDs) for liver transplantation (LT) has increased steadily, much controversy remains, and no common acceptance criteria exist with regard to donor and recipient risk factors and prediction models. A consensus conference was organized by International Liver Transplantation Society on January 31, 2020, in Venice, Italy, to review the current clinical practice worldwide regarding DCD-LT and to develop internationally accepted guidelines. The format of the conference was based on the grade system. International experts in this field were allocated to 6 working groups and prepared evidence-based recommendations to answer-specific questions considering the currently available literature. Working group members and conference attendees served as jury to edit and confirm the final recommendations presented at the end of the conference by each working group separately. This report presents the final statements and recommendations provided by working group 2, covering the entire spectrum of donor and recipient risk factors and prediction models in DCD-LT.
Jagdale, Abhijit MD1; Kumar, Vineeta MD2; Anderson, Douglas J. MD1,3; Locke, Jayme E. MD, MPH1,3; Hanaway, Michael J. MD3; Eckhoff, Devin E. MD1,3; Iwase, Hayato MD, PhD1; Cooper, David K.C. MD, PhD, FRCS1
doi : 10.1097/TP.0000000000003632
September 2021 - Volume 105 - Issue 9 - p 1904-1908
Chapman, Jeremy R. AC, FRACP, MD1
doi : 10.1097/TP.0000000000003590
September 2021 - Volume 105 - Issue 9 - p 1909-1910
Woodle, E. Steve MD1; Gebel, Howard M. PhD2; Montgomery, Robert A. MD3; Maltzman, Jonathan S. MD, PhD4,5
doi : 10.1097/TP.0000000000003859
September 2021 - Volume 105 - Issue 9 - p 1911-1913
Zhang, Yunwei MS1; Wong, Germaine PhD2; Yang, Jean Yee Hwa PhD1,3
doi : 10.1097/TP.0000000000003663
September 2021 - Volume 105 - Issue 9 - p 1914-1915
Wagener, Gebhard MD1
doi : 10.1097/TP.0000000000003451
September 2021 - Volume 105 - Issue 9 - p 1916
Sakai, Hiroshi MD1,2; Duggan, Erin M. MD, MS1,2; Griesemer, Adam D. MD1,2
doi : 10.1097/TP.0000000000003473
September 2021 - Volume 105 - Issue 9 - p 1917-1918
Afzal, Aasim M. MD1,2,3; Meyer, Dan M. MD1,4
doi : 10.1097/TP.0000000000003515
September 2021 - Volume 105 - Issue 9 - p 1919-1920
Petrisli, Evangelia MD1; Carella, Claudia MA2; Navarro, Aurora MD3; Fehily, Deirdre PhD2,4; Strong, Douglas Michael PhD5; Cardillo, Massimo MD2; on behalf of the Notify Editorial Board*
doi : 10.1097/TP.0000000000003589
September 2021 - Volume 105 - Issue 9 - p 1921-1929
World Health Assembly Resolution 63.22 mandated World Health Organization to facilitate Member State access to appropriate information on medical products of human origin (MPHO), including collecting data on serious adverse events and reactions. To meet this challenge, the Italian National Transplant Center, with a mandate from World Health Organization, has built and maintained an open-access searchable database of instructive records on disease transmission and other MPHO adverse occurrences.
Reichart, Bruno MD1; Längin, Matthias MD2; Denner, Joachim PhD3; Schwinzer, Reinhard PhD4; Cowan, Peter J. PhD5,6; Wolf, Eckhard DVM7,8
doi : 10.1097/TP.0000000000003588
September 2021 - Volume 105 - Issue 9 - p 1930-1943
Heart transplantation is the only long-lasting lifesaving option for patients with terminal cardiac failure. The number of available human organs is however far below the actual need, resulting in substantial mortality of patients while waiting for a human heart. Mechanical assist devices are used to support cardiac function but are associated with a high risk of severe complications and poor quality of life for the patients. Consistent success in orthotopic transplantation of genetically modified pig hearts into baboons indicates that cardiac xenotransplantation may become a clinically applicable option for heart failure patients who cannot get a human heart transplant. In this overview, we project potential paths to clinical cardiac xenotransplantation, including the choice of genetically modified source pigs; associated requirements of microbiological, including virological, safety; optimized matching of source pig and recipient; and specific treatments of the donor heart after explantation and of the recipients. Moreover, selection of patients and the regulatory framework will be discussed.
Wang, Xinle BSc1; MacParland, Sonya A. PhD1,2,3; Perciani, Catia T. PhD2
doi : 10.1097/TP.0000000000003598
September 2021 - Volume 105 - Issue 9 - p 1944-1956
For many individuals with end-stage liver disease, the only treatment option is liver transplantation. However, liver transplant rejection is observed in 24%–80% of transplant patients and lifelong drug regimens that follow the transplant procedure lead to serious side effects. Furthermore, the pool of donor livers available for transplantation is far less than the demand. Well-characterized and physiologically relevant models of liver transplantation are crucial to a deeper understanding of the cellular processes governing the outcomes of liver transplantation and serve as a platform for testing new therapeutic strategies to enhance graft acceptance. Such a model has been found in the rat transplant model, which has an advantageous size for surgical procedures, similar postoperative immunological progression, and high genome match to the human liver. From rat liver transplant studies published in the last 5 years, it is clear that the rat model serves as a strong platform to elucidate transplant immunological mechanisms. Using the model, we have begun to uncover potential players and possible therapeutic targets to restore liver tolerance and preserve host immunocompetence. Here, we present an overview of recent literature for rat liver transplant models, with an aim to highlight the value of the models and to provide future perspectives on how these models could be further characterized to enhance the overall value of rat models to the field of liver transplantation.
Greenberg, Rebecca RN, PhD1,2; Goldberg, Aviva MD, MA3,4; Anthony, Samantha MSW, PhD1,4,5; Buchman, Daniel Z. MSW, PhD6,7; Delaney, Sean MPH8; Gruben, Vanessa LLM4,9; Holdsworth, Sandra4; Le Foll, Bernard MD, PhD1,10; Leung, Marianna PharmD11; Lien, Dale MD12; Lynch, Marie-Josee MD1,13; Selzner, Nazia MD, PhD1,4,13; Chandler, Jennifer A. LLM4,9; Fortin, Marie-Chantal MD, PhD4,14,15
doi : 10.1097/TP.0000000000003618
September 2021 - Volume 105 - Issue 9 - p 1957-1964
Alcohol and cannabis use as a contraindication to organ transplantation is a controversial issue. Until recently, patients in Canada with alcohol-associated liver disease were required to demonstrate abstinence for 6 mo to receive a liver transplant. There is no equivalent rule that is applied consistently for cannabis use. There is some evidence that alcohol and cannabis use disorder pretransplant could be associated with worse outcomes posttransplantation. However, early liver transplantation for patients with alcohol-associated liver disease in France and in the United States has led to challenges of the 6-mo abstinence rule in Canada in the media. It has also resulted in several legal challenges arguing that the rule violates human rights laws regarding discrimination in the provision of medical services and that the rule is also unconstitutional (this challenge is still before the court). Recent legalization of cannabis use for adults in Canada has led to questions about the appropriateness of limiting transplant access based on cannabis use. The ethics committee of the Canadian Society of Transplantation was asked to provide an ethical analysis of cannabis and alcohol abstinence policies. Our conclusions were as follows: neither cannabis use nor the 6-mo abstinence rule for alcohol use should be an absolute contraindication to transplantation, and transplant could be offered to selected patients, further research should be conducted to ensure evidence-based policies; and the transplant community has a duty not to perpetuate stigma associated with alcohol and cannabis use disorders.
Ezzelarab, Mohamed B. MD1; Zhang, Hong MD, PhD1; Sasaki, Kazuki MD, PhD1; Lu, Lien BS1; Zahorchak, Alan F. MS1; van der Windt, Dirk J. MD, PhD1; Dai, Helong MD, PhD1; Perez-Gutierrez, Angelica MD1; Bhama, Jay K. MD2; Thomson, Angus W. PhD, DSc1,3
doi : 10.1097/TP.0000000000003617
September 2021 - Volume 105 - Issue 9 - p 1965-1979
Regulatory T cell (Treg) therapy is a promising approach to amelioration of allograft rejection and promotion of organ transplant tolerance. However, the fate of infused Treg, and how this relates to their therapeutic efficacy using different immunosuppressive regimens is poorly understood. Our aim was to analyze the tissue distribution, persistence, replicative activity and phenotypic stability of autologous, donor antigen alloreactive Treg (darTreg) in anti-thymocyte globulin (ATG)-lymphodepleted, heart-allografted cynomolgus monkeys.
Cao, Mengtao PhD1; Peng, Yuanzheng PhD1; Lu, Ying PhD1; Zou, Zhicheng BS1; Chen, Jiao BS1; Bottino, Rita PhD2; Knoll, Michael BS2; Zhang, Hanchen MS1; Lin, Shan PhD1; Pu, Zuhui PhD1; Sun, Liang MS3; Fang, Zhoubin BS3; Qiu, Chuanghua MS3; Dai, Yifan PhD4; Cai, Zhiming MD1; Mou, Lisha PhD1
doi : 10.1097/TP.0000000000003603
September 2021 - Volume 105 - Issue 9 - p 1980-1988
Type 1 diabetes (T1DM) is a chronic autoimmune disease characterized by T-cell–mediated destruction of insulin-producing beta cells. Evidence shows that patients with T1DM and mice used in specific diabetic models both exhibit changes in their intestinal microbiota and dysregulated microbiota contributes to the pathogenesis of T1DM. Islet transplantation (Tx) is poised to play an important role in the treatment of T1DM. However, whether treatment of T1DM with islet Tx can rescue dysregulated microbiota remains unclear.
Kageyama, Shoichi MD1; Kadono, Kentaro MD1; Hirao, Hirofumi MD1; Nakamura, Kojiro MD1; Ito, Takahiro MD1; Gjertson, David W. PhD2,3; Sosa, Rebecca A. PhD3; Reed, Elaine F. PhD3; Kaldas, Fady M. MD1; Busuttil, Ronald W. MD1; Kupiec-Weglinski, Jerzy W. PhD1; Zhai, Yuan PhD1
doi : 10.1097/TP.0000000000003488
September 2021 - Volume 105 - Issue 9 - p 1989-1997
A major discrepancy between clinical and most experimental settings of liver ischemia-reperfusion injury (IRI) is the allogenicity.
Sasaki, Kazunari MD1; Nair, Amit MD1; Firl, Daniel J. MD2; McVey, John C. BA1; El-Gazzaz, Galal MD1; Diago Uso, Teresa MD1; Fujiki, Masato MD, PhD1; Aucejo, Federico N. MD1; Quintini, Cristiano MD1; Kwon, Choon-Hyuck D. MD, PhD1; Hashimoto, Koji MD, PhD1; Miller, Charles M. MD1; Eghtesad, Bijan MD1
doi : 10.1097/TP.0000000000003458
September 2021 - Volume 105 - Issue 9 - p 1998-2006
Rates of withdrawal of life-sustaining treatment are higher among critically ill pediatric patients compared to adults. Therefore, livers from pediatric donation after circulatory death (pDCD) could improve graft organ shortage and waiting time for listed patients. As knowledge on the utilization of pDCD is limited, this study used US national registry data (2002–2017) to estimate the prognostic impact of pDCD in both adult and pediatric liver transplant (LT).
Kusakabe, Jiro MD, PhD1; Yagi, Shintaro MD, PhD1; Sasaki, Kazunari MD2; Uozumi, Ryuji PhD3; Abe, Hiroyasu PhD3; Okamura, Yusuke MD, PhD1; Taura, Kojiro MD, PhD1; Kaido, Toshimi MD, PhD1; Uemoto, Shinji MD, PhD1
doi : 10.1097/TP.0000000000003472
September 2021 - Volume 105 - Issue 9 - p 2007-2017
Several studies reported favorable outcomes of small-for-size grafts with graft-to-recipient weight ratio (GRWR) <0.8% in living-donor liver transplantation (LDLT). However, their indications should be carefully determined because they must have been indicated for low-risk cases over larger grafts with 0.8% ? GRWR. Furthermore, evidence for minimum requirements of GRWR remains inconclusive. We investigated the safety of small-for-size grafts against larger grafts by adjusting for confounding risk factors, and minimum requirement of graft volume in adult LDLT.
Acho, Christine DO1; Morita, Yoshihisa MD1; Fernandez, Valeria MD2; Safwan, Mohamed MBBS2; Galusca, Dragos MD1; Abouljoud, Marwan MD, FACS2; Yoshida, Atsushi MD, FACS2; El-Bashir, Jaber MD1; Nagai, Shunji MD, PhD, FACS2
doi : 10.1097/TP.0000000000003450
September 2021 - Volume 105 - Issue 9 - p 2018-2028
Fast-track anesthesia in liver transplantation (LT) has been discussed over the past few decades; however, factors associated with immediate extubation after LT surgery are not well defined. This study aimed to identify predictive factors and examine impacts of immediate extubation on post-LT outcomes.
Haque, Mohammed E. MD1,2; Badenoch, Adam D. BMBS1,2; Orlov, David MD1,2; Selzner, Markus MD, PhD3,4; McCluskey, Stuart A. MD, PhD1,2,4
doi : 10.1097/TP.0000000000003452
September 2021 - Volume 105 - Issue 9 - p 2029-2036
Early extubation of liver transplantation recipients is a cornerstone of fast-track (FT) pathways. Identifying suitable candidates has previously been accomplished using perioperative variables to develop a FT probability score. The objective of this study was to externally validate a proposed FT score.
Wallace, David MSc1,2; Cowling, Thomas E. PhD1; Walker, Kate PhD1; Suddle, Abid MD2; Gimson, Alex MD3; Rowe, Ian PhD4,5; Callaghan, Chris PhD6; Heaton, Nigel FRCS2; van der Meulen, Jan PhD1; Bernal, William MD2
doi : 10.1097/TP.0000000000003484
September 2021 - Volume 105 - Issue 9 - p 2037-2044
Impaired pretransplant performance status (PS) is associated with chronic liver disease (CLD). We studied its impact on hospital length of stay (LOS), complications, and readmissions in the first year after liver transplantation.
Zhou, Shengmei MD1,2; Mitsinikos, Tania MD2,3; Emamaullee, Juliet MD, PhD2,4; Weaver, Carly BA4; Wang, Larry MD, PhD1,2; Shillingford, Nick MD1,2; Warren, Mikako MD1,2; Bawab, Julie Huss MD1; Tiwari, Nishant MD1; Genyk, Yuri MD2,4; Thomas, Danny MD2,3; Parham, David M. MD1,2
doi : 10.1097/TP.0000000000003469
September 2021 - Volume 105 - Issue 9 - p 2045-2053
An early and accurate diagnosis of liver antibody-mediated rejection (AMR) followed by timely intervention is important for clinical management but remains challenging. The aim of this study was to assess the clinicopathologic characteristics and outcomes of late acute AMR in pediatric liver transplantation recipients.
Barah, Masoud PhD1; Mehrotra, Sanjay PhD1,2,3
doi : 10.1097/TP.0000000000003620
September 2021 - Volume 105 - Issue 9 - p 2054-2071
Despite the kidney supply shortage, 18%–20% of deceased donor kidneys are discarded annually in the United States. In 2018, 3569 kidneys were discarded.
Permpalung, Nitipong MD, MPH1,2; Bazemore, Katrina MPH3; Chiang, Teresa Po-Yu MD, MPH4; Mathew, Joby DPT, MS3; Barker, Lindsay RN, BSN3; Nematollahi, Saman MD1; Cochran, Willa CRNP4; Sait, Afrah S. MD1; Avery, Robin K. MD1; Shah, Pali D. MD3
doi : 10.1097/TP.0000000000003839
September 2021 - Volume 105 - Issue 9 - p 2072-2079
The impacts of COVID-19 on lung allograft function, rejection, secondary infection, and clinical outcomes in lung transplant recipients (LTRs) remain unknown.
Butts, Ryan J. MD1; Baez Hernandez, Nathanya MD1; Kirk, Richard FRCP1; Bano, Maria MD1; Davies, Ryan MD2
doi : 10.1097/TP.0000000000003514
September 2021 - Volume 105 - Issue 9 - p 2080-2085
Pediatric donor heart acceptability differs among transplant centers. However, the impact of center donor acceptance on waitlist and posttransplant outcomes has not been investigated. The aim of our study was to investigate associations between transplant center refusal rate (RR) and outcomes after listing.
Christensen, Anders Haugom MD1,2,3; Nygaard, Sissel MD1,2; Rolid, Katrine PT, MSc2,4,5; Nytrøen, Kari PT, PhD2,4; Gullestad, Lars MD, PhD2,4,5; Fiane, Arnt MD, PhD2,6; Thaulow, Erik MD, PhD1,2; Døhlen, Gaute MD, PhD1; Saul, J. Philip MD7; Wyller, Vegard B.B. MD, PhD2,8
doi : 10.1097/TP.0000000000003580
September 2021 - Volume 105 - Issue 9 - p 2086-2096
Heart transplantation (HTx) surgically transects all connections to the heart, including the autonomic nerves. We prospectively examined signs, timing and consequences of early sympathetic and parasympathetic sinoatrial reinnervation, as well as explored indirect evidence of afferent cardiopulmonary reinnervation.
Huckaby, Lauren V. MD, MS1; Hickey, Gavin MD2; Sultan, Ibrahim MD3; Kilic, Arman MD3
doi : 10.1097/TP.0000000000003602
September 2021 - Volume 105 - Issue 9 - p 2097-2103
The 2018 heart allocation change has resulted in greater frequency of high-risk bridging to orthotopic heart transplantation (OHT). Although survival has been studied in these patients, functional status outcomes are less established. This study evaluated changes in functional status of OHT survivors based on bridging strategy.
Chu, Nadia M. PhD, MPH1,2; Chen, Xiaomeng MSPH1; Bae, Sunjae KMD, PhD1; Brennan, Daniel C. MD1; Segev, Dorry L. MD, PhD1,2; McAdams-DeMarco, Mara A. PhD1,2
doi : 10.1097/TP.0000000000003608
September 2021 - Volume 105 - Issue 9 - p 2104-2111
With stressors of dialysis prekidney transplantation (KT) and restoration of kidney function post-KT, it is likely that KT recipients experience a decline in functional status while on the waitlist and improvements post-KT.
Doberer, Konstantin MD1; Haupenthal, Frederik Cand. Med.1; Nackenhorst, Maja MD2; Bauernfeind, Florian BS1; Dermuth, Florentina Cand. Med.1; Eigenschink, Michael Cand. Med.1; Schiemann, Martin MD1; Kläger, Johannes MD2; Görzer, Irene MD, PhD3; Eskandary, Farsad MD, PhD1; Reindl-Schwaighofer, Roman MD, PhD1; Kiki?, Željko MD4; Böhmig, Georg MD1; Strassl, Robert MD5; Regele, Heinz MD2; Puchhammer-Stöckl, Elisabeth MD3; Bond, Gregor MD, PhD1
doi : 10.1097/TP.0000000000003619
September 2021 - Volume 105 - Issue 9 - p 2112-2118
Nonpathogenic torque teno viruses (TTVs) are highly prevalent in transplant recipients and associated with immunosuppression. Studies in kidney transplant patients have proposed assessment of TTV load for risk stratification of clinically overt graft rejection. The value of TTV quantification in the context of subclinical rejection has not been evaluated.
Ou, Michael T. BS1; Boyarsky, Brian J. MD, PhD1; Chiang, Teresa P.Y. MD, MPH1; Bae, Sunjae PhD1; Werbel, William A. MD2; Avery, Robin K. MD2; Tobian, Aaron A.R. MD, PhD3; Massie, Allan B. PhD1; Segev, Dorry L. MD, PhD1,4; Garonzik-Wang, Jacqueline M. MD, PhD1
doi : 10.1097/TP.0000000000003824
September 2021 - Volume 105 - Issue 9 - p 2119-2123
Belatacept may impair humoral immunity, impacting the effectiveness of SARS-CoV-2 mRNA vaccines in transplant recipients. We investigated immunogenicity after SARS-CoV-2 mRNA vaccines in kidney transplant recipients who are and are not taking belatacept.
Chavarot, Nathalie MD1,2; Ouedrani, Amani PhD2,3,4; Marion, Olivier MD5,6,7; Leruez-Ville, Marianne MD, PhD2,8; Vilain, Estelle BSN1; Baaziz, Maroua MD1,2; Del Bello, Arnaud MD5,6,7; Burger, Carole MD1,2; Sberro-Soussan, Rebecca MD1,2; Martinez, Frank MD1,2; Chatenoud, Lucienne MD, PhD2,3,4; Abravanel, Florence PhD5,6,9; Anglicheau, Dany MD, PhD1,2; Izopet, Jacques PhD5,6,9; Couat, Chloé NP7; Zuber, Julien MD, PhD1,2; Legendre, Christophe MD1,2; Lanternier, Fanny MD, PhD2,10; Kamar, Nassim MD, PhD5,6,7; Scemla, Anne MD1,2
doi : 10.1097/TP.0000000000003784
September 2021 - Volume 105 - Issue 9 - p e94-e95
Panayi, Adriana C. MD1; Kauke, Martin MD1; Pomahac, Bohdan MD1
doi : 10.1097/TP.0000000000003789
September 2021 - Volume 105 - Issue 9 - p e96-e98
Dolff, Sebastian MD, PhD1; Korth, Johannes MD2; Jahn, Michael MD2; Kribben, Andreas MD2; Witzke, Oliver MD1; Wilde, Benjamin MD2
doi : 10.1097/TP.0000000000003812
September 2021 - Volume 105 - Issue 9 - p e99
Meshram, Hari Shankar MD, DM1; Kute, Vivek B. MD, DM, FCRP (London)1; Shah, Nauka MD1; Chauhan, Sanshriti MD1; Navadiya, Vijay V. MD1; Patel, Ansy H. MBBS2; Patel, Himanshu V. MD, DNB, FCRP (London)1; Engineer, Divyesh MD, DM1; Banerjee, Subho MD, DM1; Rizvi, Jamal MS, MCh3; Mishra, Vineet V. MD, FCRP (London)4
doi : 10.1097/TP.0000000000003835
September 2021 - Volume 105 - Issue 9 - p e100-e103
Ali, Nicole M. MD1; Alnazari, Nasser MD1; Mehta, Sapna A. MD1; Boyarsky, Brian MD2; Avery, Robin K. MD2; Segev, Dorry L. MD, PhD2; Montgomery, Robert A. MD, DPhil1; Stewart, Zoe A. MD, PhD1
doi : 10.1097/TP.0000000000003836
September 2021 - Volume 105 - Issue 9 - p e104-e106
Menteer, Jondavid MD1,2; Goldbeck, Cameron MS2,3; Herrington, Cynthia MD1,2; Yanni, George MD2,4; Emamaullee, Juliet A. MD, PhD, FACS2,3
doi : 10.1097/TP.0000000000003810
September 2021 - Volume 105 - Issue 9 - p e107-e108
Justo, Iago MD, PhD1,2; Caso, Óscar MD, PhD1,2; Marcacuzco, Alberto MD, PhD1,2; García-Conde, María MD, PhD1; Jiménez-Romero, Carlos MD, PhD1,2
doi : 10.1097/TP.0000000000003796
September 2021 - Volume 105 - Issue 9 - p e109-e110
Bonetti, Antonella PhD1; Sponga, Sandro MD2; Livi, Ugolino MD1,2; Ortolani, Fulvia PhD1
doi : 10.1097/TP.0000000000003795
September 2021 - Volume 105 - Issue 9 - p e111-e112
doi : 10.1097/TP.0000000000003894
September 2021 - Volume 105 - Issue 9 - p e113
Do you want to add Medilib to your home screen?